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RANTES has been implicated in the allergic inflammation of asthma by promoting the migration
and activation of the inflammatory cells, including eosinophils. The study was undertaken to
evaluate RANTES levels in the exhaled breath condensate (EBC) of asthmatics with different
degrees of asthma severity.
EBC was collected from 33 patients with allergic asthma (11 with steroid-naı¨ve mild asthma,
10 with ICS-treated, stable mild-to-moderate asthma, 12 with ICS-treated unstable, severe
asthma) and seven healthy volunteers.
In the three groups of asthmatics, RANTES concentrations in EBC were significantly higher
compared with healthy volunteers. RANTES levels were significantly higher in patients with
unstable asthma than in the two groups with stable disease. We observed statistically signifi-
cant correlations between the concentrations of RANTES in EBC and FENO in the three studied
groups of asthmatics; notably, the correlation between the parameters described above was
strong positive in the group of unstable and steroid-naı¨ve stable asthmatics. We also discov-
ered a significantly positive correlation between RANTES in EBC and the serum ECP or blood
eosinophil count in the groups of asthmatics with severe, unstable asthma and between
RANTES and serum ECP in the group of steroid-naı¨ve stable asthmatics.
Measurements of RANTES in EBC may provide another useful diagnostic tool for detecting
and monitoring inflammation in patients with asthma.
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Chemokines are a family of cytokines that are believed to
be involved in the pathogenesis of asthma, possibly by
recruiting leukocytes to the inflammatory site.1 The CC
chemokines, such as RANTES and eotaxin, have been impli-
cated in the allergic inflammation of asthma by promoting.
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ing eosinophils.2
In many studies performed using invasive (such as
bronchoalveolar lavage e BAL) as well as semi-invasive
(e.g. induced sputum) methods in asthmatic patients, an
increased expression of local and systemic CC chemokines
has been demonstrated.3,4 However, these relatively
invasive approaches are unsuitable for repeated monitoring
of airway inflammation.
By contrast, exhaled breath condensate (EBC), collected
by cooling exhaled air, is a non-invasive, easily performed,
rapid and effort-independent method for obtaining samples
from the lower respiratory tract. There has been increasing
interest in measuring EBC e a very useful method, espe-
cially in the assessment of inflammatory mediators related
to the bronchial epithelium, in the pathophysiology and
evaluation of new strategies for the treatment of asthma.5
The aim of the study was to assess RANTES concentra-
tions in the EBC of asthmatics with different degrees of
asthma severity, and to establish the possible correlation of
these measurements with the other parameters of airway
inflammation.
Material and methods
Patients
The study was performed upon groups of 11 steroid-naı¨ve
mild allergic asthma patients; 10 patients treated with
inhaled corticosteroids (ICS) with stable, mild-to-moderate
allergic asthma; and 12 ICS-treated patients with severe,
unstable allergic asthma. Asthma was diagnosed according
to the criteria recommended by the GINA 2002.6 The
steroid-naı¨ve asthmatics have not been treated with ICS.
They were free from acute exacerbations and respiratory
tract infections during the 3 months prior to the study.
The patients with stable, mild-to-moderate asthma had
been treated with low to medium doses of ICS at a constant
dose for at least 3 months. Stable asthma was defined as
a minimal need for rescue medications (short-acting
b2-agonists), no exacerbations, and no use of systemic ste-
roids in the previous 12 months. The patients with severe,
unstable asthma had required one or more hospitalizations
for asthma and more than three oral steroid bursts in the
last year. They had been taking high-doses of ICS and
long-acting b2-agonists for at least 6 months. Patients
who had respiratory tract infections in the last month be-
fore the study were excluded from this study. All the pa-
tients were atopic and sensitized to common inhaled
allergens, as evaluated by skin prick tests.
Seven healthy subjects were recruited for the study as
a negative control group. They were free of respiratory
tract infection within 3 months prior to the study and from
other significant illnesses known to affect exhaled nitric
oxide (FENO) measurements. Asthma patients and healthy
volunteers were non-smokers and during the last year had
not been passive smokers.
All of the patients and healthy volunteers were examined
by a physician, then underwent EBC collection, FENO mea-
surement, and spirometry. Blood samples were collected to
determine serum total IgE, ECP and blood eosinophil count.The study protocol was approved by the Ethics of
Research Committee of the Medical University of Bialystok,
number of agreement: R-I-003/80/2006. Informed consent
was obtained from every patient entered in the study.
Measurements
Exhaled nitric oxide (FENO) was measured by the chemilumi-
nescence technique using a Sievers 280i NO Analyzer
(Boulder, Colorado, USA). The measurements were per-
formed at an expiratory flow of 50 ml/s according to ATS
recommendations for on-linemeasurement of FENO in adults.
7
The spirometry (FEV1) was performed using a Master-
Screen Pneumo PC spirometer (Jaeger, Hoechberg,
Germany), according to ATS standards.8
EBC was collected by using a commercially available
condenser (EcoScreen; Erich Jaeger GmbH, Hoechberg,
Germany) according to the current ATS/ERS guidelines.5
All measurements were performed at the same time
(between 8.00e10.00 am) to avoid possible circadian
rhythm of mediator concentrations in EBC. All patients
were asked to refrain from eating and drinking before EBC
collecting.
Exhaled air entered and left the chamber through one-
way valves and the inlet and outlet, thus keeping the
chamber closed. A low temperature inside the condensing
chamber throughout the collection time produced a cooling
down sample. The temperature of collection was around
0 C.5,9 Patients were instructed to breathe tidally for
10 min with nose clip. The respiratory rate ranged from
15e20 breaths/minute. Patients were asked to swallow
their saliva periodically and to temporarily discontinue
collection if they needed to cough. At the end of collection
1.5 to 3.5 ml aliquots of condensate were transferred to
Eppendorf tubes and immediately frozen. Samples were
stored at 80 C.10
Serum total IgE concentrations and serum ECP were
measured using ImmunoCAP Technology (Pharmacia
Diagnostics, Uppsala, Sweden). The minimum detectable
level of ECP was 2.0 mg/l. Blood eosinophil count was
measured using a hematologic analyzer (Coulter Electron-
ics GmbH, Miami, Florida, USA). The concentrations of
RANTES (R&D Systems, Wiesbaden-Nordenstadt, Ger-
many) in EBC were determined using an enzyme-linked
immunosorbent assay. The minimum detectable level
was 2.0 pg/ml.
Analysis
Statistical significance was analyzed by using analysis of
variance (ANOVA) followed by Bonferroni’s t test post hoc
to determine statistical differences. All values were
expressed as means SD; p values <0.05 were considered
significant. The relationship between studied parameters
was assayed by correlation. Pearson’s linear correlation
coefficient was used.
Results
Characteristics of patients and healthy volunteers are
presented in Table 1.
Table 1 Characteristics of study subjects and healthy volunteers
Characteristics Dimension Healthy volunteers Stable asthma,
steroid naı¨ve
Stable asthma,
ICS-treated
Unstable.
asthma
Number of patients 7 11 10 12
Sex F/M 4/3 6/5 6/4 8/4
Age Years 28.00 4.93 27.36 7.50 44.70 8.11 46.16 5.54
Duration of symptoms Years 2.54 1.21b,c 8.60 3.86a,c 15.83 6.87a,b
Baseline FEV1 % Predicted 106.85 9.7b,c 95.63 18.54c 83.60 6.61c 55.08 11.91a,b
Serum total IgE
concentration
kU/l 65.42 31.65a,b,c 327.9 265.6 275.0 88.60 316.6 116.2
Blood eosinophil count cells/mm3 51 26a,b,c 239 138 271 70 317 112
FENO ppB 18.00 5.59a,b,c 76.00 33.66b 38.70 10.26a,c 76.33 27.26b
RANTES (EBC) pg/ml 3.56 0.78a,b,c 10.56 3.01b,c 8.18 1.94a,c 20.33 2.29a,b
ECP (serum) mg/l 3.52 0.71a,b,c 12.28 4.02c 11.09 2.87c 21.46 9.75a,c
Data are presented as medians (ranges).
FEV1, forced expiratory volume in one second.
a Values significantly different from patients with stable, steroid-naı¨ve asthma, p< 0.05.
b Values significantly different from patients with stable, ICS-treated asthma, p< 0.05.
c Values significantly different from patients with unstable asthma, p< 0.05.
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RANTES were significantly higher than those detected in
healthy volunteers (steroid-naı¨ve stable asthma: 10.56
3.01 pg/ml, p< 0.001; ICS-treated stable asthma: 8.18
1.94, p< 0.001; unstable asthma: 20.33 2.29, p< 0.001;
healthy volunteers: 3.56 0.78) (Fig. 1). RANTES levels
were very strongly elevated in patients with unstable
asthma compared with ICS-treated stable asthma patients
(p< 0.001) and steroid-naı¨ve asthma patients (p< 0.001).
The concentrations obtained in the steroid-naı¨ve asthma
patients group were significantly higher than in the ICS-
treated stable asthma group (pZ 0.046).
We observed statistically significant correlations
between the concentrations of RANTES in EBC and FENO in
the three studied groups of asthmatics; these correlations
were strong positive in the group of unstable and steroid-
naı¨ve stable asthmatics. There were no correlations
between RANTES in EBC and FENO in the group of healthy
volunteers. We discovered a significantly positive correla-
tion between RANTES in EBC and serum ECP or blood
eosinophil count in the group of asthmatics with severe,Figure 1 Concentrations of RANTES in EBC in studied groups
of asthma patients and healthy volunteers.unstable asthma and between RANTES and serum ECP in
the group of steroid-naı¨ve stable asthmatics. Statistically
significant correlations between RANTES in EBC and other
studied parameters were not observed in any studied
groups of asthmatics or healthy volunteers (Table 2).
Discussion
Eosinophilic infiltration into affected tissue is one of the
hallmarks of allergic inflammation. Airway eosinophilia has
been demonstrated in asthmatic individuals as compared
with normal controls.11 Airway eosinophilia is a hallmark of
asthma exacerbation. Coordination of cytokines such as
interleukin-5 (IL-5), eotaxin, and RANTES seems to be
necessary for eosinophil extravasation including adhesion,
chemotaxis, and activation.2 In vitro studies have
demonstrated the specificity of these eosinophil-selective
cytokines for attraction and activation of eosinophils, and
imply their participation in the specific recruitment of
eosinophils to sites of allergic inflammation.12,13
RANTES, a member of the Cys-Cys (CC) chemokines, is
produced by endothelium cells, fibroblasts, T-lymphocytes,
eosinophils, platelets, and other cells.14 RANTES is a potent
chemoattractant for eosinophils, T-lymphocytes, basophils,
monocytes/macrophages, and mast cells.14 It also activates
these immune cells and induces the exocytosis of broncho-
constrictive mediators, such as histamine and cysteinyl
leukotrienes from basophils and eosinophilic cationic
protein from eosinophils.14 Therefore, RANTES might be
involved in inflammatory cell recruitment and the induction
of bronchoconstrictive mediators from cells resulting in
airflow limitation.
Evidence for an in vivo role of RANTES as a chemoattrac-
tant in allergic inflammation derives from a study showing
that neutralization of RANTES with a receptor antagonist
significantly inhibits both lymphocyte and eosinophil
recruitment.15 Teran et al. have reported that RANTES is
a major eosinophil attractant in the bronchoalveolar lavage
fluid of asthmatic patients exposed to an allergen
Table 2 Correlations between concentrations RANTES in EBC and other studied parameters in the groups of asthma patients
and healthy volunteers
Studied groups FENO Serum ECP Blood eosinophil
count
Serum total IgE Baseline FEV1
Healthy volunteers rZ 0.28 rZ 0.30 rZ 0.70 rZ0.23 rZ0.04
pZ 0.53 pZ 0.50 pZ 0.08 pZ 0.61 pZ 0.92
Stable asthma steroid-naı¨ve rZ 0.94 rZ 0.87 rZ 0.43 rZ 0.13 rZ0.15
p< 0.001 p< 0.001 pZ 0.18 pZ 0.27 pZ 0.65
Stable asthma ICS-treated rZ 0.63 rZ 0.52 rZ 0.37 rZ0.01 rZ 0.23
pZ 0.048 pZ 0.12 pZ 0.21 pZ 0.96 pZ 0.47
Unstable asthma rZ 0.93 rZ 0.77 rZ 0.72 rZ 0.41 rZ0.35
p< 0.001 pZ 0.003 pZ 0.008 pZ 0.09 pZ 0.24
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lates with BAL eosinophil count.16 Increased RANTES
mRNA expression has been demonstrated in bronchial
biopsies taken from both allergic and non-allergic asth-
matics. The increase in the expression of RANTES mRNA
and immunoreactivity at these sites significantly correlated
with tissue eosinophil numbers.17 The levels of this
chemokine can be used to predict the development of
bronchial hyperreactivity and bronchoconstriction.15,18
Corticosteroids are currently the most effective anti-
inflammatory agents in the treatment of asthma. Therapy
with inhaled corticosteroids leads to a decrease in counts of
inflammatory cells (such as eosinophils and T-lymphocytes)
and a reduction in the expression of pro-inflammatory
cytokines in the airways.19 Studies performed by Wang
et al. have demonstrated that human bronchial epithelial
cells are capable of releasing RANTES. This release is signifi-
cantly attenuated by corticosteroids.20 John et al. suggest
that steroids are effective in reducing airway inflammation
in asthma by limiting both RANTES and an IL-8-induced influx
of inflammatory cells in the airways.21
EBC examination being simple and non-invasive could be
exploited to detect specific levels of biomarkers and
monitor the severity of disease in response to appropriate
prescribed therapy.9 There is one report concerning the
possibilities for measurement of RANTES concentrations in
EBC in patients with asthma. Matsunaga et al. have
indicated that the level of RANTES in EBC was significantly
upregulated in asthmatic airways compared with that of
healthy subjects, and that it significantly correlates with
the degree of bronchial obturation.18
Our study shows that RANTES levels in EBC are higher in
asthmatic patients than in healthy controls. In patients
with unstable asthma, levels of RANTES were significantly
higher than in steroid-naı¨ve and ICS-treated patients with
stable asthma.
This observation is confirmed by previous studies
performed by Tillie-Leblond et al.22 They reveal, that CC
chemokines (including RANTES) are present at high levels
in BAL from patients with severe asthmatic exacerbation;
these levels are higher than in patients with mild asthma.
The authors suggest that CC chemokines could participate
not only in eosinophil recruitment but also in other inflam-
matory processes associated with severe asthma.
Our results show that, concentrations of RANTES in EBC
significantly correlate with exhaled nitric oxide levels ea more and more appreciable criterion for the evaluation
of airway inflammation e in the all studied groups.23
RANTES also correlates with other laboratory tests
commonly associated with asthma, such as elevated levels
of eosinophil cationic protein (unstable asthma, steroid-
naı¨ve stable asthma) and peripheral blood eosinophilia
(unstable asthma). We have recorded statistically signifi-
cant lower levels of RANTES in the group of ICS-treated
mild-to-moderate asthmatics compared to steroid-naı¨ve
mild allergic asthma patients. This could suggest the
beneficial effect of ICS-treatment in down-regulation of
RANTES in the airways. However, more studies are needed
to establish the influence of ICS on RANTES levels in EBC.
Measurements of RANTES in the EBC of asthma patients
may provide another useful diagnostic tool for detecting
and monitoring inflammation, disease severity, and
responses to treatment.
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